Mark Kleinman, Sky News’ City editor, posted on X, the service formerly known as Twitter: “Revealed: Merck (MRK), the US-listed pharma group, ...
Shares of Merck & Co. Inc. MRK dropped 0.02% to $96.54 Tuesday, on what proved to be an all-around mixed trading session for ...
Merck (MRK) declared a quarterly dividend of 81c per share of the company’s common stock for Q1 of 2025. Payment will be made on January 8, ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.81 per share of the company’s common stock ...
Incyte (NASDAQ:INCY) shares seesawed and are now down 10% amid a posting about potential takeover speculation from Merck (MRK ...
Merck & Co. Inc.’s reported positive results Tuesday for a new, easier-to-administer formulation of its blockbuster cancer ...
Merck (MRK) stock gains as its subcutaneously delivered pembrolizumab meets key goals in Phase 3 trial against intravenous ...
We recently compiled a list of the Jim Cramer Talked About These 11 Stocks Recently. In this article, we are going to take a ...
Zacks.com on MSN4d
Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer TherapyMerck MRK announced that it has entered into an exclusive licensing deal with China-based privately-held biotech company ...
Goldman reiterates the Buy rating for Merck stock, decreasing the price target from $139 to $135, reflecting lowered resetting of Gardasil forecasts. BMO Capital Markets suggests that Merck's ...
In my view, based on what's coming up for Merck, it's likely that investors with some patience will find the stock to be more appealing. Understanding the investment thesis for Merck requires ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback